Billionaire Stan Druckenmiller Is Betting On AI Infrastructure, Tobacco and Industrial Stocks

4. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Holders: 60  

Duquesne Capital’s Stake: $213,860,000

Natera, Inc. (NASDAQ:NTRA) operates as a diagnostics company that develops and commercializes molecular testing services worldwide. Some of the prominent products of the firm include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, and Horizon carrier screening test for individuals and couples to determine if they are carriers of genetic variations that cause certain genetic conditions. The firm recently posted earnings for the second quarter of 2024, reporting losses per share of $0.30, beating market expectations by $0.40. The revenue over the period was more than $413 million, up close to 58% year-on-year and surpassing analyst estimates by a handsome $70 million.

Natera, Inc. (NASDAQ:NTRA) is a quality stock in the biotech world, evidenced by Wall Street analysis of the firm. Morgan Stanley analyst Tejas Savant has an Overweight rating on the shares with a price target of $132. Following the earnings report of the firm, the investment advisory noted that the premium multiple on the stock was justified by multiple drivers of near- and long-term estimate upside and a clear line-of-sight to profitable and self-sustaining growth.